可溶性 HLA Ⅰ类分子在体外对爱泼斯坦-巴尔病毒（EBV）特异性 CD8 + 细胞毒性T淋巴细胞（CTL）活性的抑制作用。
Inhibition of Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocyte (CTL) activity by soluble HLA class I in vitro.
作者信息
Gansuvd B, Hagihara M, Munkhbat B, Kanai N, Morita N, Munkhtuvshin N, Chargui J, Kato S, Hotta T, Tsuji K
机构信息
Department of Haematology, Institute of Clinical Pathology, Ulaanbaatar, Mongolia, Japan.
出版信息
Clin Exp Immunol. 2000 Jan;119(1):107-14. doi: 10.1046/j.1365-2249.2000.01092.x.
In the present study, the effects of soluble HLA (sHLA) class I molecules against EBV-specific CTL were examined. Two different sources of sHLA class I, either bioengineered spliced form of HLA-B7 (sB7) or natural production from EBV-transformed B cells (natural sHLA), were added during the induction of CTL or incubated with MHC-restricted CD8+ CTL, which were selected by immunobeads just before testing for their cytotoxic activity. Both sB7 and natural sHLA class I blocked the generation of CD8+ CTL and also inhibited the cytotoxic activity of established CTL in a dose-dependent manner. In both ways, natural sHLA class I was effective in 10-fold lower concentrations compared with sB7. The inhibitory effect did not require a sharing of the HLA allotypes between sHLA and the CTL. CTL, after being treated with sHLA, underwent apoptosis, which was considered here as the main mechanism.
在本研究中，检测了可溶性HLA（sHLA）I类分子对EBV特异性CTL的影响。在CTL诱导过程中添加两种不同来源的sHLA I类分子，即生物工程拼接形式的HLA - B7（sB7）或EBV转化的B细胞天然产生的（天然sHLA），或者与MHC限制性CD8 + CTL一起孵育，这些CTL在测试其细胞毒性活性之前通过免疫磁珠进行筛选。sB7和天然sHLA I类分子均以剂量依赖性方式阻断CD8 + CTL的产生，并抑制已建立的CTL的细胞毒性活性。在这两种情况下，天然sHLA I类分子在浓度比sB7低10倍时仍有效。抑制作用并不要求sHLA和CTL之间共享HLA同种异型。用sHLA处理后的CTL发生凋亡，在此被认为是主要机制。
Zotero 插件